Previous close | 78.90 |
Open | 73.03 |
Bid | 78.55 |
Ask | 82.85 |
Strike | 90.00 |
Expiry date | 2026-01-16 |
Day's range | 73.03 - 73.03 |
Contract range | N/A |
Volume | |
Open interest | 2 |
FDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Imfinzi.
The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.55 per share.
AbbVie (NYSE: ABBV) today announced that the independent directors of the board have selected Roxanne S. Austin as lead independent director, effective July 1, 2024. Ms. Austin succeeds Glenn F. Tilton, who has served as lead independent director since 2013. Mr. Tilton will continue to serve on the AbbVie Board as an independent director.